{"id":54710,"date":"2026-01-19T22:41:45","date_gmt":"2026-01-19T14:41:45","guid":{"rendered":"https:\/\/flcube.com\/?p=54710"},"modified":"2026-01-19T22:41:47","modified_gmt":"2026-01-19T14:41:47","slug":"dualitys-db-1317-adc-receives-ind-approval-for-adam9-targeted-solid-tumor-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54710","title":{"rendered":"Duality\u2019s DB\u20111317 ADC Receives IND Approval for ADAM9\u2011Targeted Solid Tumor Therapy"},"content":{"rendered":"\n<p><strong>Duality Biologics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9606:HKG\">HKG: 9606<\/a>) announced that its <strong>ADAM9\u2011targeting ADC candidate DB\u20111317<\/strong> has received <strong>Investigational New Drug (IND) approval<\/strong> from China\u2019s <strong>CDE of NMPA<\/strong> for a <strong>monotherapy trial in patients with advanced or metastatic solid tumors<\/strong>, advancing the first\u2011in\u2011class therapy into human studies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Duality Biologics (9606.HK)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>DB\u20111317 (ADAM9\u2011targeting ADC)<\/td><\/tr><tr><td><strong>Platform<\/strong><\/td><td>Proprietary DITAC platform<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>IND (Investigational New Drug)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>CDE of NMPA (China)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced or metastatic solid tumors<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Monotherapy Phase\u202fI trial<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>14\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Rights<\/strong><\/td><td>Global rights retained by Duality<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> <strong>ADAM9<\/strong> (A Disintegrin and Metalloproteinase 9) \u2013 highly expressed in <strong>gastric, colorectal, pancreatic, NSCLC, and other solid tumors<\/strong>, with low expression in normal tissue<\/li>\n\n\n\n<li><strong>Platform:<\/strong> <strong>DITAC (Duality\u2011Integrated Toxin\u2011Antibody Conjugate)<\/strong> \u2013 proprietary ADC technology enabling <strong>stable linker chemistry<\/strong> and <strong>bystander effect<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> DB\u20111317 binds ADAM9 on tumor cells, internalizes, and releases a <strong>cytotoxic payload<\/strong>, inducing <strong>targeted cell death<\/strong> while sparing healthy cells<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> <strong>First ADAM9\u2011targeted ADC<\/strong> in clinical development; preclinical studies show <strong>promising anti\u2011tumor activity<\/strong> across multiple cancer models<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>ADAM9\u2011Positive Solid Tumors<\/strong><\/td><td>480,000<\/td><td>2.1\u202fmillion<\/td><\/tr><tr><td><strong>Advanced\/Metastatic Cases<\/strong><\/td><td>192,000<\/td><td>840,000<\/td><\/tr><tr><td><strong>ADC Market (2030E)<\/strong><\/td><td>\u00a518\u202fbillion<\/td><td>$14\u202fbillion<\/td><\/tr><tr><td><strong>DB\u20111319 Peak Revenue (2032E)<\/strong><\/td><td>\u00a52.8\u202fbillion<\/td><td>$1.9\u202fbillion<\/td><\/tr><tr><td><strong>Penetration Rate<\/strong><\/td><td>0\u202f%<\/td><td>0\u202f%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADAM9 Targeting:<\/strong><\/li>\n\n\n\n<li><strong>M1231<\/strong> (Mersana Therapeutics) \u2013 ADC in Phase\u202fI (undisclosed target)<\/li>\n\n\n\n<li><strong>No other ADAM9 ADCs<\/strong> in active clinical development<\/li>\n\n\n\n<li><strong>TEAD Inhibitors<\/strong> (downstream of Hippo pathway): <strong>Signet Therapeutics<\/strong> (SIGX2649) in preclinical stage<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> DB\u20111317\u2019s <strong>high ADAM9 specificity<\/strong> and <strong>DITAC platform<\/strong> offer <strong>potential for superior efficacy and safety<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-next-steps\">Strategic Positioning &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> Duality\u2019s <strong>Guangzhou ADC facility<\/strong> (capacity 5,000\u202fL) will produce DB\u20111317 for clinical trials; commercial scale\u2011up planned for 2028<\/li>\n\n\n\n<li><strong>Clinical Development:<\/strong> <strong>Phase\u202fI initiation<\/strong> expected <strong>Q2\u202f2026<\/strong> in China; <strong>US IND filing<\/strong> planned for <strong>H2\u202f2026<\/strong> leveraging China data<\/li>\n\n\n\n<li><strong>Combination Potential:<\/strong> ADAM9 expression correlates with <strong>immunotherapy resistance<\/strong>; future studies may combine DB\u20111317 with <strong>PD\u20111 inhibitors<\/strong><\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Deal validates <strong>DITAC platform<\/strong> for <strong>first\u2011in\u2011class targets<\/strong>, supporting pipeline expansion<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial projections for DB\u20111317. Actual results may differ due to clinical trial outcomes, competitive dynamics, and manufacturing challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Duality Biologics (HKG: 9606) announced that its ADAM9\u2011targeting ADC candidate DB\u20111317 has received Investigational New&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,16,62,232],"class_list":["post-54710","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-clinical-trial-approval-initiation","tag-duality-biologics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Duality\u2019s DB\u20111317 ADC Receives IND Approval for ADAM9\u2011Targeted Solid Tumor Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Duality Biologics (HKG: 9606) announced that its ADAM9\u2011targeting ADC candidate DB\u20111317 has received Investigational New Drug (IND) approval from China\u2019s CDE of NMPA for a monotherapy trial in patients with advanced or metastatic solid tumors, advancing the first\u2011in\u2011class therapy into human studies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54710\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Duality\u2019s DB\u20111317 ADC Receives IND Approval for ADAM9\u2011Targeted Solid Tumor Therapy\" \/>\n<meta property=\"og:description\" content=\"Duality Biologics (HKG: 9606) announced that its ADAM9\u2011targeting ADC candidate DB\u20111317 has received Investigational New Drug (IND) approval from China\u2019s CDE of NMPA for a monotherapy trial in patients with advanced or metastatic solid tumors, advancing the first\u2011in\u2011class therapy into human studies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54710\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-19T14:41:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-19T14:41:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54710#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54710\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Duality\u2019s DB\u20111317 ADC Receives IND Approval for ADAM9\u2011Targeted Solid Tumor Therapy\",\"datePublished\":\"2026-01-19T14:41:45+00:00\",\"dateModified\":\"2026-01-19T14:41:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54710\"},\"wordCount\":380,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Duality Biologics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54710#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54710\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54710\",\"name\":\"Duality\u2019s DB\u20111317 ADC Receives IND Approval for ADAM9\u2011Targeted Solid Tumor Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-19T14:41:45+00:00\",\"dateModified\":\"2026-01-19T14:41:47+00:00\",\"description\":\"Duality Biologics (HKG: 9606) announced that its ADAM9\u2011targeting ADC candidate DB\u20111317 has received Investigational New Drug (IND) approval from China\u2019s CDE of NMPA for a monotherapy trial in patients with advanced or metastatic solid tumors, advancing the first\u2011in\u2011class therapy into human studies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54710#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54710\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54710#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Duality\u2019s DB\u20111317 ADC Receives IND Approval for ADAM9\u2011Targeted Solid Tumor Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Duality\u2019s DB\u20111317 ADC Receives IND Approval for ADAM9\u2011Targeted Solid Tumor Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Duality Biologics (HKG: 9606) announced that its ADAM9\u2011targeting ADC candidate DB\u20111317 has received Investigational New Drug (IND) approval from China\u2019s CDE of NMPA for a monotherapy trial in patients with advanced or metastatic solid tumors, advancing the first\u2011in\u2011class therapy into human studies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54710","og_locale":"en_US","og_type":"article","og_title":"Duality\u2019s DB\u20111317 ADC Receives IND Approval for ADAM9\u2011Targeted Solid Tumor Therapy","og_description":"Duality Biologics (HKG: 9606) announced that its ADAM9\u2011targeting ADC candidate DB\u20111317 has received Investigational New Drug (IND) approval from China\u2019s CDE of NMPA for a monotherapy trial in patients with advanced or metastatic solid tumors, advancing the first\u2011in\u2011class therapy into human studies.","og_url":"https:\/\/flcube.com\/?p=54710","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-19T14:41:45+00:00","article_modified_time":"2026-01-19T14:41:47+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54710#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54710"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Duality\u2019s DB\u20111317 ADC Receives IND Approval for ADAM9\u2011Targeted Solid Tumor Therapy","datePublished":"2026-01-19T14:41:45+00:00","dateModified":"2026-01-19T14:41:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54710"},"wordCount":380,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Cancer","Clinical trial approval \/ initiation","Duality Biologics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54710#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54710","url":"https:\/\/flcube.com\/?p=54710","name":"Duality\u2019s DB\u20111317 ADC Receives IND Approval for ADAM9\u2011Targeted Solid Tumor Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-19T14:41:45+00:00","dateModified":"2026-01-19T14:41:47+00:00","description":"Duality Biologics (HKG: 9606) announced that its ADAM9\u2011targeting ADC candidate DB\u20111317 has received Investigational New Drug (IND) approval from China\u2019s CDE of NMPA for a monotherapy trial in patients with advanced or metastatic solid tumors, advancing the first\u2011in\u2011class therapy into human studies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54710#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54710"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54710#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Duality\u2019s DB\u20111317 ADC Receives IND Approval for ADAM9\u2011Targeted Solid Tumor Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54710"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54710\/revisions"}],"predecessor-version":[{"id":54711,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54710\/revisions\/54711"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54710"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54710"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}